Pemetrexed-induced scleroderma-like changes in the lower legs

Pemetrexed (Alimta(®)) is a new-generation antifolate used to treat malignant pleural mesothelioma and non-small cell lung cancer (NSCLC). We report two cases of a new toxicity induced by pemetrexed: scleroderma-like induration of the lower extremities. The first case concerned a 66-year-old man dia...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annales de dermatologie et de vénéréologie 2015-02, Vol.142 (2), p.115-120
Hauptverfasser: Corbaux, C, Marie, J, Meraud, J-P, Lacroix, S, Delhoume, J-Y, Jouary, T, Madoui, S
Format: Artikel
Sprache:fre
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 120
container_issue 2
container_start_page 115
container_title Annales de dermatologie et de vénéréologie
container_volume 142
creator Corbaux, C
Marie, J
Meraud, J-P
Lacroix, S
Delhoume, J-Y
Jouary, T
Madoui, S
description Pemetrexed (Alimta(®)) is a new-generation antifolate used to treat malignant pleural mesothelioma and non-small cell lung cancer (NSCLC). We report two cases of a new toxicity induced by pemetrexed: scleroderma-like induration of the lower extremities. The first case concerned a 66-year-old man diagnosed with pulmonary adenocarcinoma metastatic from the outset and in whom maintenance treatment comprised pemetrexed after first-line therapy comprising six courses of cisplatin-pemetrexed. After the fourth cycle of pemetrexed, he presented an erythematous oedema of the left leg, which was subsequently bilateral. Clinically, there was painful cellulitis associated with areas of bruising. The lesions had an appearance of erysipeloid-like infection, and there was no fever. The second case concerned a 70-year-old woman diagnosed with metastatic NSCLC. From the first course of pemetrexed, given as maintenance therapy, she presented erythematous oedema of both legs, without fever. After the second course, we observed the recurrence of the lesions consisting of erythemato-violaceous plaques on both legs, with severe bilateral indurated and painful oedema, associated with major functional disability. A diagnosis of bilateral erysipelas was made, and antibiotic treatment with cloxacillin was given. In both cases, pemetrexed was discontinued and the local outcome was very slowly favourable, with persistence of scleroderma. This cutaneous adverse effect is unrecognized, resulting in delayed diagnosis. It is often initially confused with bilateral erysipelas, despite absence of fever. According to some studies, the severity of the cutaneous toxicity may be connected with patients' folate status. Thus folate and vitamin B12 supplementation combined with dexamethasone could decrease the incidence of this side effect. There was no recurrence and no worsening with taxanes, chemotherapy agents known to induce scleroderma. We feel that this cutaneous toxicity must be recognised on account of its potential severity.
doi_str_mv 10.1016/j.annder.2014.11.011
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1653131842</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1653131842</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-3c0f400bec43fdebba97ca15de31b400d1227287a6be2fd27967e906c1829bf33</originalsourceid><addsrcrecordid>eNo1j71OwzAURj2AaCm8AUIZWRJ87dhJBgZUUUCqBAPMkX9u2hTHCXYi4O2JRJm-4Rwd6SPkCmgGFOTtIVPeWwwZo5BnABkFOCFLCgLSSvJyQc5jPFAKrOTijCyYECKXki_J3St2OAb8Rpu23k4GbRKNw9DPuU6lrv3AxOyV32FMWp-Me0xc_4UhcbiLF-S0US7i5XFX5H3z8LZ-Srcvj8_r-206MIAx5YY2OaUaTc4bi1qrqjAKhEUOegYWGCtYWSipkTWWFZUssKLSQMkq3XC-Ijd_3SH0nxPGse7aaNA55bGfYg1ScOBQ5mxWr4_qpDu09RDaToWf-v8y_wVgS1gh</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1653131842</pqid></control><display><type>article</type><title>Pemetrexed-induced scleroderma-like changes in the lower legs</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Corbaux, C ; Marie, J ; Meraud, J-P ; Lacroix, S ; Delhoume, J-Y ; Jouary, T ; Madoui, S</creator><creatorcontrib>Corbaux, C ; Marie, J ; Meraud, J-P ; Lacroix, S ; Delhoume, J-Y ; Jouary, T ; Madoui, S</creatorcontrib><description>Pemetrexed (Alimta(®)) is a new-generation antifolate used to treat malignant pleural mesothelioma and non-small cell lung cancer (NSCLC). We report two cases of a new toxicity induced by pemetrexed: scleroderma-like induration of the lower extremities. The first case concerned a 66-year-old man diagnosed with pulmonary adenocarcinoma metastatic from the outset and in whom maintenance treatment comprised pemetrexed after first-line therapy comprising six courses of cisplatin-pemetrexed. After the fourth cycle of pemetrexed, he presented an erythematous oedema of the left leg, which was subsequently bilateral. Clinically, there was painful cellulitis associated with areas of bruising. The lesions had an appearance of erysipeloid-like infection, and there was no fever. The second case concerned a 70-year-old woman diagnosed with metastatic NSCLC. From the first course of pemetrexed, given as maintenance therapy, she presented erythematous oedema of both legs, without fever. After the second course, we observed the recurrence of the lesions consisting of erythemato-violaceous plaques on both legs, with severe bilateral indurated and painful oedema, associated with major functional disability. A diagnosis of bilateral erysipelas was made, and antibiotic treatment with cloxacillin was given. In both cases, pemetrexed was discontinued and the local outcome was very slowly favourable, with persistence of scleroderma. This cutaneous adverse effect is unrecognized, resulting in delayed diagnosis. It is often initially confused with bilateral erysipelas, despite absence of fever. According to some studies, the severity of the cutaneous toxicity may be connected with patients' folate status. Thus folate and vitamin B12 supplementation combined with dexamethasone could decrease the incidence of this side effect. There was no recurrence and no worsening with taxanes, chemotherapy agents known to induce scleroderma. We feel that this cutaneous toxicity must be recognised on account of its potential severity.</description><identifier>ISSN: 0151-9638</identifier><identifier>DOI: 10.1016/j.annder.2014.11.011</identifier><identifier>PMID: 25554663</identifier><language>fre</language><publisher>France</publisher><subject>Aged ; Antineoplastic Agents - adverse effects ; Drug Eruptions - etiology ; Female ; Humans ; Leg ; Male ; Pemetrexed - adverse effects ; Scleroderma, Localized - chemically induced</subject><ispartof>Annales de dermatologie et de vénéréologie, 2015-02, Vol.142 (2), p.115-120</ispartof><rights>Copyright © 2014 Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25554663$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Corbaux, C</creatorcontrib><creatorcontrib>Marie, J</creatorcontrib><creatorcontrib>Meraud, J-P</creatorcontrib><creatorcontrib>Lacroix, S</creatorcontrib><creatorcontrib>Delhoume, J-Y</creatorcontrib><creatorcontrib>Jouary, T</creatorcontrib><creatorcontrib>Madoui, S</creatorcontrib><title>Pemetrexed-induced scleroderma-like changes in the lower legs</title><title>Annales de dermatologie et de vénéréologie</title><addtitle>Ann Dermatol Venereol</addtitle><description>Pemetrexed (Alimta(®)) is a new-generation antifolate used to treat malignant pleural mesothelioma and non-small cell lung cancer (NSCLC). We report two cases of a new toxicity induced by pemetrexed: scleroderma-like induration of the lower extremities. The first case concerned a 66-year-old man diagnosed with pulmonary adenocarcinoma metastatic from the outset and in whom maintenance treatment comprised pemetrexed after first-line therapy comprising six courses of cisplatin-pemetrexed. After the fourth cycle of pemetrexed, he presented an erythematous oedema of the left leg, which was subsequently bilateral. Clinically, there was painful cellulitis associated with areas of bruising. The lesions had an appearance of erysipeloid-like infection, and there was no fever. The second case concerned a 70-year-old woman diagnosed with metastatic NSCLC. From the first course of pemetrexed, given as maintenance therapy, she presented erythematous oedema of both legs, without fever. After the second course, we observed the recurrence of the lesions consisting of erythemato-violaceous plaques on both legs, with severe bilateral indurated and painful oedema, associated with major functional disability. A diagnosis of bilateral erysipelas was made, and antibiotic treatment with cloxacillin was given. In both cases, pemetrexed was discontinued and the local outcome was very slowly favourable, with persistence of scleroderma. This cutaneous adverse effect is unrecognized, resulting in delayed diagnosis. It is often initially confused with bilateral erysipelas, despite absence of fever. According to some studies, the severity of the cutaneous toxicity may be connected with patients' folate status. Thus folate and vitamin B12 supplementation combined with dexamethasone could decrease the incidence of this side effect. There was no recurrence and no worsening with taxanes, chemotherapy agents known to induce scleroderma. We feel that this cutaneous toxicity must be recognised on account of its potential severity.</description><subject>Aged</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Drug Eruptions - etiology</subject><subject>Female</subject><subject>Humans</subject><subject>Leg</subject><subject>Male</subject><subject>Pemetrexed - adverse effects</subject><subject>Scleroderma, Localized - chemically induced</subject><issn>0151-9638</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j71OwzAURj2AaCm8AUIZWRJ87dhJBgZUUUCqBAPMkX9u2hTHCXYi4O2JRJm-4Rwd6SPkCmgGFOTtIVPeWwwZo5BnABkFOCFLCgLSSvJyQc5jPFAKrOTijCyYECKXki_J3St2OAb8Rpu23k4GbRKNw9DPuU6lrv3AxOyV32FMWp-Me0xc_4UhcbiLF-S0US7i5XFX5H3z8LZ-Srcvj8_r-206MIAx5YY2OaUaTc4bi1qrqjAKhEUOegYWGCtYWSipkTWWFZUssKLSQMkq3XC-Ijd_3SH0nxPGse7aaNA55bGfYg1ScOBQ5mxWr4_qpDu09RDaToWf-v8y_wVgS1gh</recordid><startdate>20150201</startdate><enddate>20150201</enddate><creator>Corbaux, C</creator><creator>Marie, J</creator><creator>Meraud, J-P</creator><creator>Lacroix, S</creator><creator>Delhoume, J-Y</creator><creator>Jouary, T</creator><creator>Madoui, S</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20150201</creationdate><title>Pemetrexed-induced scleroderma-like changes in the lower legs</title><author>Corbaux, C ; Marie, J ; Meraud, J-P ; Lacroix, S ; Delhoume, J-Y ; Jouary, T ; Madoui, S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-3c0f400bec43fdebba97ca15de31b400d1227287a6be2fd27967e906c1829bf33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>fre</language><creationdate>2015</creationdate><topic>Aged</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Drug Eruptions - etiology</topic><topic>Female</topic><topic>Humans</topic><topic>Leg</topic><topic>Male</topic><topic>Pemetrexed - adverse effects</topic><topic>Scleroderma, Localized - chemically induced</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Corbaux, C</creatorcontrib><creatorcontrib>Marie, J</creatorcontrib><creatorcontrib>Meraud, J-P</creatorcontrib><creatorcontrib>Lacroix, S</creatorcontrib><creatorcontrib>Delhoume, J-Y</creatorcontrib><creatorcontrib>Jouary, T</creatorcontrib><creatorcontrib>Madoui, S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Annales de dermatologie et de vénéréologie</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Corbaux, C</au><au>Marie, J</au><au>Meraud, J-P</au><au>Lacroix, S</au><au>Delhoume, J-Y</au><au>Jouary, T</au><au>Madoui, S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pemetrexed-induced scleroderma-like changes in the lower legs</atitle><jtitle>Annales de dermatologie et de vénéréologie</jtitle><addtitle>Ann Dermatol Venereol</addtitle><date>2015-02-01</date><risdate>2015</risdate><volume>142</volume><issue>2</issue><spage>115</spage><epage>120</epage><pages>115-120</pages><issn>0151-9638</issn><abstract>Pemetrexed (Alimta(®)) is a new-generation antifolate used to treat malignant pleural mesothelioma and non-small cell lung cancer (NSCLC). We report two cases of a new toxicity induced by pemetrexed: scleroderma-like induration of the lower extremities. The first case concerned a 66-year-old man diagnosed with pulmonary adenocarcinoma metastatic from the outset and in whom maintenance treatment comprised pemetrexed after first-line therapy comprising six courses of cisplatin-pemetrexed. After the fourth cycle of pemetrexed, he presented an erythematous oedema of the left leg, which was subsequently bilateral. Clinically, there was painful cellulitis associated with areas of bruising. The lesions had an appearance of erysipeloid-like infection, and there was no fever. The second case concerned a 70-year-old woman diagnosed with metastatic NSCLC. From the first course of pemetrexed, given as maintenance therapy, she presented erythematous oedema of both legs, without fever. After the second course, we observed the recurrence of the lesions consisting of erythemato-violaceous plaques on both legs, with severe bilateral indurated and painful oedema, associated with major functional disability. A diagnosis of bilateral erysipelas was made, and antibiotic treatment with cloxacillin was given. In both cases, pemetrexed was discontinued and the local outcome was very slowly favourable, with persistence of scleroderma. This cutaneous adverse effect is unrecognized, resulting in delayed diagnosis. It is often initially confused with bilateral erysipelas, despite absence of fever. According to some studies, the severity of the cutaneous toxicity may be connected with patients' folate status. Thus folate and vitamin B12 supplementation combined with dexamethasone could decrease the incidence of this side effect. There was no recurrence and no worsening with taxanes, chemotherapy agents known to induce scleroderma. We feel that this cutaneous toxicity must be recognised on account of its potential severity.</abstract><cop>France</cop><pmid>25554663</pmid><doi>10.1016/j.annder.2014.11.011</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0151-9638
ispartof Annales de dermatologie et de vénéréologie, 2015-02, Vol.142 (2), p.115-120
issn 0151-9638
language fre
recordid cdi_proquest_miscellaneous_1653131842
source MEDLINE; Elsevier ScienceDirect Journals
subjects Aged
Antineoplastic Agents - adverse effects
Drug Eruptions - etiology
Female
Humans
Leg
Male
Pemetrexed - adverse effects
Scleroderma, Localized - chemically induced
title Pemetrexed-induced scleroderma-like changes in the lower legs
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T17%3A22%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pemetrexed-induced%20scleroderma-like%20changes%20in%20the%20lower%20legs&rft.jtitle=Annales%20de%20dermatologie%20et%20de%20v%C3%A9n%C3%A9r%C3%A9ologie&rft.au=Corbaux,%20C&rft.date=2015-02-01&rft.volume=142&rft.issue=2&rft.spage=115&rft.epage=120&rft.pages=115-120&rft.issn=0151-9638&rft_id=info:doi/10.1016/j.annder.2014.11.011&rft_dat=%3Cproquest_pubme%3E1653131842%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1653131842&rft_id=info:pmid/25554663&rfr_iscdi=true